A Form 4 filed on August 18, 2026, disclosed that John S. Montalbano, a director of AbCellera Biologics Inc. (NASDAQ:ABCL), purchased 10,000 common shares on August 18, 2026.

Key Highlights

  • Reporting person: John S. Montalbano, listed as a Director of AbCellera Biologics Inc.
  • Transaction: Purchase (code P) of 10,000 common shares on August 18, 2026, at a price of $11.03 per share.
  • Direct ownership following transaction: 251,000 common shares held directly.
  • Indirect ownership: 5,000 common shares held indirectly by spouse.
  • No derivative securities were reported in Table II of the filing.

Montalbano's Share Purchase and Beneficial Ownership at AbCellera Biologics

According to the filing, John S. Montalbano, a director of AbCellera Biologics Inc., acquired 10,000 common shares on August 18, 2026, at a price of $11.03 per share. The transaction is coded "P," indicating an open-market purchase. The form was signed by Tryn Stimart as attorney-in-fact on August 18, 2026.

Following the reported transaction, the filing discloses that Montalbano directly beneficially owns 251,000 common shares. In addition, 5,000 common shares are reported as indirectly owned, with the nature of that indirect ownership identified as "By Spouse." No derivative securities were reported acquired, disposed of, or beneficially owned in Table II of the filing.

The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934. No amendment date was indicated, and the form was filed by one reporting person. The issuer is identified as AbCellera Biologics Inc., trading on NASDAQ:ABCL.

What Was Disclosed

The Form 4 reported a purchase of 10,000 common shares of AbCellera Biologics Inc. by director John S. Montalbano at $11.03 per share on August 18, 2026, resulting in direct beneficial ownership of 251,000 shares and indirect ownership of 5,000 shares through a spouse.